Carmignac Gestion’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-85,271
| Closed | -$1.58M | – | 163 |
|
|
2023
Q3 | $1.58M | Buy |
+85,271
| New | +$965K | 0.03% | 107 |
|
|
2017
Q3 | – | Sell |
-2,035,592
| Closed | -$246M | – | 82 |
|
|
2017
Q2 | $246M | Buy |
2,035,592
+7,400
| +0.4% | +$857K | 2% | 21 |
|
|
2017
Q1 | $229M | Buy |
2,028,192
+5,400
| +0.3% | +$630K | 1.76% | 24 |
|
|
2016
Q4 | $220M | Buy |
2,022,792
+7,600
| +0.4% | +$905K | 1.71% | 26 |
|
|
2016
Q3 | $332M | Buy |
2,015,192
+21,600
| +1% | +$3.41M | 2.48% | 16 |
|
|
2016
Q2 | $284M | Buy |
1,993,592
+326,855
| +20% | +$47.7M | 2.43% | 18 |
|
|
2016
Q1 | $214M | Buy |
1,666,737
+346,850
| +26% | +$41M | 2.09% | 22 |
|
|
2015
Q4 | $197M | Buy |
1,319,887
+380
| +0% | +$64.3K | 2.17% | 19 |
|
|
2015
Q3 | $219M | Sell |
1,319,507
-5,100
| -0.4% | -$1.12M | 2.77% | 17 |
|
|
2015
Q2 | $320M | Sell |
1,324,607
-24,780
| -2% | -$6.6M | 2.85% | 15 |
|
|
2015
Q1 | $381M | Sell |
1,349,387
-82,684
| -6% | -$17.9M | 3.37% | 14 |
|
|
2014
Q4 | $223M | Buy |
1,432,071
+101,555
| +8% | +$18.8M | 2.04% | 22 |
|
|
2014
Q3 | $315M | Buy |
1,330,516
+329,940
| +33% | +$84.1M | 2.69% | 18 |
|
|
2014
Q2 | $237M | Buy |
+1,000,576
| New | +$264M | 1.85% | 24 |
|
Carmignac Gestion's ICPT Position: Q4 2023 in Review
Carmignac Gestion sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q4 2023, closing a stake of 85,271 shares — an estimated $1.58M sold.
Carmignac Gestion first reported a position in ICPT in Q2 2014 and held it in 14 quarters. The position peaked at $381M in Q1 2015. 0 funds tracked by Wall St. Rank hold ICPT as of Q4 2023.
- Carmignac Gestion reported no remaining Intercept Pharmaceuticals, Inc. position as of Q4 2023 after selling out during the quarter.
- Carmignac Gestion sold 85,271 Intercept Pharmaceuticals, Inc. shares in Q4 2023, an estimated $1.58M.
- Carmignac Gestion first reported a position in Intercept Pharmaceuticals, Inc. in Q2 2014 and held it in 14 quarters.
- Carmignac Gestion's Intercept Pharmaceuticals, Inc. position peaked at $381M in Q1 2015.
- 0 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q4 2023.
Based on Carmignac Gestion's 13F filing for Q4 2023, filed 13 Feb 2024.